Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study was written by Martin, Miguel;Zielinski, Christoph;Ruiz-Borrego, Manuel;Carrasco, Eva;Ciruelos, Eva M.;Munoz, Montserrat;Bermejo, Begona;Margeli, Mireia;Csoszi, Tibor;Anton, Antonio;Turner, Nicholas;Casas, Maria I.;Morales, Serafin;Alba, Emilio;Calvo, Lourdes;de la Haba-Rodriguez, Juan;Ramos, Manuel;Murillo, Laura;Santaballa, Ana;Alonso-Romero, Jose L.;Sanchez-Rovira, Pedro;Corsaro, Massimo;Huang, Xin;Thallinger, Christiane;Kahan, Zsuzsanna;Gil-Gil, Miguel. And the article was included in European Journal of Cancer in 2022.Application of 1211441-98-3 This article mentions the following:
An earlier anal. of the PEARL phase III study showed that palbociclib plus endocrine therapy (ET) does not improve progression-free survival (PFS) over capecitabine in aromatase inhibitor-resistant, hormone receptor-pos./human epidermal growth factor receptor 2-neg. metastatic breast cancer (MBC) patients. Here, we report the final overall survival (OS) anal.Postmenopausal patients (N = 601) were randomized 1:1 to capecitabine or palbociclib plus ET (exemestane, Cohort 1; fulvestrant, Cohort 2). OS was analyzed in Cohort 2, the wild-type ESR1 population and the overall population. Addnl., we analyzed subsequent systemic therapies and explored PFS2 (time from randomization to the end of the first subsequent therapy/death).OS was 31.1 mo for palbociclib plus fulvestrant and 32.8 mo for capecitabine (adjusted hazard ratio [aHR] 1.10, 95% confidence interval [CI] 0.81-1.50, P = 0.550). In the wild-type ESR1 population, OS was 37.2 mo for palbociclib plus ET and 34.8 mo for capecitabine (aHR 1.06, 95% CI 0.81-1.37, P = 0.683). In OS analyses, no subgroup showed superiority for palbociclib plus ET over capecitabine. OS in the overall population was 32.6 mo for palbociclib plus ET and 30.9 mo for capecitabine (P = 0.995). Subsequent systemic therapy was given to 79.8% and 82.9% of patients with palbociclib plus ET and capecitabine, resp. Median PFS2 was similar between study arms (Cohort 2, P = 0.941; wild-type ESR1 population, P = 0.827). No new safety findings were observedPalbociclib plus ET did not show a statistically superior OS compared to capecitabine in MBC patients progressing on aromatase inhibitors.NCT02028507 (ClinTrials.gov), 2013-003170-27 (EudraCT). In the experiment, the researchers used many compounds, for example, 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (cas: 1211441-98-3Application of 1211441-98-3).
7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (cas: 1211441-98-3) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Application of 1211441-98-3
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics